FOXO TECHNOLOGIES INC. ANNOUNCES INTENTION TO SPIN OFF EPIGENETICS SUBSIDIARY
FOXO Technologies Inc. (NYSE American: FOXO) has announced its Board's approval to pursue the spin-off of its subsidiary, FOXO Labs, Inc., which specializes in epigenetics technology. The subsidiary owns Patent No. 11,817,214 for machine learning models that determine biochemical states using DNA epigenetic data.
FOXO Labs utilizes saliva-based epigenetic biomarkers to provide health, lifestyle, and longevity insights, eliminating the need for invasive blood and urine collection. The company is developing an AI-powered health coaching system that combines wearable data with epigenetic analysis to deliver personalized wellness guidance.
The spin-off aims to create a subscription-based revenue model for personal health and longevity, with FOXO Technologies maintaining partial ownership while allowing shareholders to benefit from direct ownership in FOXO Labs.
FOXO Technologies Inc. (NYSE American: FOXO) ha annunciato l'approvazione del proprio Consiglio di Amministrazione per procedere con la scissione della sua controllata, FOXO Labs, Inc., specializzata in tecnologia epigenetica. La controllata detiene il Brevetto n. 11.817.214 per modelli di apprendimento automatico che determinano stati biochimici utilizzando dati epigenetici del DNA.
FOXO Labs utilizza biomarcatori epigenetici basati sulla saliva per fornire informazioni su salute, stile di vita e longevità, eliminando la necessità di prelievi invasivi di sangue e urine. L'azienda sta sviluppando un sistema di coaching sanitario basato sull'intelligenza artificiale che combina dati da dispositivi indossabili con analisi epigenetiche per offrire consigli personalizzati sul benessere.
La scissione mira a creare un modello di ricavi basato su abbonamenti per la salute personale e la longevità, con FOXO Technologies che manterrà una partecipazione parziale, consentendo però agli azionisti di beneficiare della proprietà diretta di FOXO Labs.
FOXO Technologies Inc. (NYSE American: FOXO) ha anunciado la aprobación de su Junta Directiva para llevar a cabo la escisión de su subsidiaria, FOXO Labs, Inc., especializada en tecnología epigenética. La subsidiaria posee la Patente No. 11,817,214 para modelos de aprendizaje automático que determinan estados bioquímicos utilizando datos epigenéticos del ADN.
FOXO Labs utiliza biomarcadores epigenéticos basados en saliva para ofrecer información sobre salud, estilo de vida y longevidad, eliminando la necesidad de recolección invasiva de sangre y orina. La compañía está desarrollando un sistema de coaching de salud impulsado por IA que combina datos de dispositivos portátiles con análisis epigenéticos para brindar orientación personalizada de bienestar.
La escisión busca crear un modelo de ingresos basado en suscripciones para la salud personal y la longevidad, con FOXO Technologies manteniendo una propiedad parcial mientras permite que los accionistas se beneficien de la propiedad directa en FOXO Labs.
FOXO Technologies Inc. (NYSE American: FOXO)는 자회사인 FOXO Labs, Inc.의 분사를 추진하기로 이사회의 승인을 받았다고 발표했습니다. 이 자회사는 DNA 후생유전학 데이터를 활용해 생화학적 상태를 판단하는 머신러닝 모델에 대한 특허번호 11,817,214를 보유하고 있습니다.
FOXO Labs는 타액 기반 후생유전학 바이오마커를 사용하여 침습적인 혈액 및 소변 채취 없이 건강, 생활습관, 장수에 관한 인사이트를 제공합니다. 회사는 웨어러블 데이터와 후생유전학 분석을 결합한 AI 기반 건강 코칭 시스템을 개발 중이며, 이를 통해 개인 맞춤형 웰빙 가이드를 제공합니다.
이번 분사의 목적은 개인 건강과 장수를 위한 구독 기반 수익 모델을 만드는 것이며, FOXO Technologies는 일부 지분을 유지하면서 주주들이 FOXO Labs의 직접 소유로부터 이익을 얻을 수 있도록 할 예정입니다.
FOXO Technologies Inc. (NYSE American : FOXO) a annoncé l'approbation de son conseil d'administration pour procéder à la scission de sa filiale, FOXO Labs, Inc., spécialisée dans la technologie épigénétique. La filiale détient le brevet n° 11 817 214 pour des modèles d'apprentissage automatique déterminant les états biochimiques à partir de données épigénétiques de l'ADN.
FOXO Labs utilise des biomarqueurs épigénétiques basés sur la salive pour fournir des informations sur la santé, le mode de vie et la longévité, supprimant ainsi le besoin de prélèvements sanguins et urinaires invasifs. L'entreprise développe un système de coaching santé alimenté par l'IA, combinant les données des objets connectés avec l'analyse épigénétique afin d'offrir des conseils personnalisés en bien-être.
La scission vise à créer un modèle de revenus par abonnement pour la santé personnelle et la longévité, FOXO Technologies conservant une participation partielle tout en permettant aux actionnaires de bénéficier d'une propriété directe dans FOXO Labs.
FOXO Technologies Inc. (NYSE American: FOXO) hat die Genehmigung seines Vorstands bekannt gegeben, die Abspaltung seiner Tochtergesellschaft FOXO Labs, Inc. voranzutreiben, die auf Epigenetik-Technologie spezialisiert ist. Die Tochtergesellschaft besitzt das Patent Nr. 11.817.214 für maschinelle Lernmodelle, die biochemische Zustände anhand von DNA-Epigenetikdaten bestimmen.
FOXO Labs nutzt epigenetische Biomarker aus Speichel, um Einblicke in Gesundheit, Lebensstil und Langlebigkeit zu geben, wodurch invasive Blut- und Urinproben entfallen. Das Unternehmen entwickelt ein KI-gestütztes Gesundheitscoaching-System, das Wearable-Daten mit epigenetischer Analyse kombiniert, um personalisierte Wellness-Empfehlungen zu liefern.
Die Abspaltung zielt darauf ab, ein abonnementbasiertes Erlösmodell für persönliche Gesundheit und Langlebigkeit zu schaffen, wobei FOXO Technologies eine Teilbeteiligung behält und gleichzeitig den Aktionären ermöglicht, direktes Eigentum an FOXO Labs zu erhalten.
- Development of innovative saliva-based epigenetic testing technology eliminates need for invasive procedures
- Ownership of valuable Patent No. 11,817,214 for machine learning models in epigenetic data analysis
- Creation of subscription-based revenue model through personalized AI health coaching
- Shareholders will benefit from direct ownership in FOXO Labs while FOXO Technologies retains partial ownership
- Execution risks associated with the spin-off process
- Potential uncertainty around timeline and implementation of the separation
- New business model yet to be proven in the market
Insights
FOXO's spin-off of its epigenetics subsidiary aims to unlock shareholder value through focused business models and direct ownership opportunities.
FOXO Technologies' decision to spin off its FOXO Labs subsidiary represents a strategic corporate restructuring aimed at unleashing value currently trapped within its conglomerate structure. The spin-off creates two distinct entities: the original FOXO Technologies and a new standalone FOXO Labs focused exclusively on epigenetics. This separation allows each business to pursue tailored strategies without competing for resources or management attention.
The transaction structure is particularly noteworthy – existing FOXO shareholders will directly own shares in the newly independent FOXO Labs while FOXO Technologies will retain partial ownership in the spun-off entity. This dual-benefit approach gives shareholders both pure-play exposure to the epigenetics business and continued participation through FOXO's retained stake.
FOXO Labs brings significant intellectual assets to this separation, including Patent No. 11,817,214 for machine learning models using DNA epigenetic data. Their technology allows health insights from non-invasive saliva samples rather than traditional blood/urine collection, creating potential for widespread consumer adoption.
The strategic rationale centers on creating a subscription-based revenue model for personal health and longevity – a high-margin business model with recurring revenue potential. By combining epigenetic biomarkers with AI coaching capabilities and integrating data from wearable devices, FOXO Labs is positioning for the growing personalized health analytics market.
While spin-offs often create value by allowing focused capital allocation and management attention, execution will be critical. The timeline remains undefined ("as soon as practical"), and shareholders should watch for upcoming regulatory filings detailing the precise mechanics and timeline of this transaction.
WEST PALM BEACH, FLORIDA, July 18, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary that is focused on the development of its epigenetics business
Our Epigenetics subsidiary has been serving as a pioneer in the development and integration of epigenetic biomarkers into state-of-the-art underwriting protocols and consumer engagement tools and owns Patent No. 11,817,214 titled "Machine Learning Model Trained to Determine a Biochemical State and/or Medical Condition Using DNA Epigenetic Data.
Epigenetic technology has been proven to provide health, lifestyle, and longevity insights that have never before been accessible to humans—from just a single saliva sample. Using saliva-based epigenetic biomarkers, we’re eliminating the need for invasive blood and urine collection, allowing us to provide scientists with advanced epigenetic testing services and bioinformatics tools that support ground-breaking research.
“We are creating the ultimate health, fitness, and longevity coach leveraging our cutting-edge patented epigenetic analysis and a new proprietary AI model to deliver a deeply personalized coaching experience. Our AI coach first utilizes existing wellness data from wearable’s to offer hyper personalized foundational lifestyle guidance. Then, through unlocking deeper epigenetic analyses, we take a web of complex biological data and simplify it into an easily actionable plan to completely transform people’s journeys in health and wellness”, said Mark White, Chief Executive Officer of FOXO Labs, Inc. “We believe spinning this business off creates the best opportunity to deliver our business strategy and create value for FOXO and its shareholders.”
“We believe FOXO Labs, Inc., is an exciting opportunity to build a subscription-based revenue model for personal health and longevity,” said Seamus Lagan, Chief Executive Officer of FOXO Technologies, Inc. “We believe a spin off whereby FOXO shareholders benefit from directly owning FOXO Labs, Inc. and by FOXO Technologies, Inc., retaining some ownership in the spun off Company, is a strategy that facilitates a simplified business model for each entity. We look forward to delivering this spin off as soon as practical.”
About FOXO Technologies Inc. (“FOXO”)
FOXO owns and operates three subsidiaries.
Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital located in East Tennessee.
Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs.
FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.
For more information about FOXO, visit www.foxotechnologies.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended ("Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s businesses; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive markets or industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Sebastien Sainsbury
ssainsbury@foxotechnologies.com
(561) 485-0151
FAQ
What is FOXO Technologies planning to spin off in 2025?
How will the FOXO Labs spin-off benefit FOXO shareholders?
What technology does FOXO Labs (NYSE American: FOXO) use for health analysis?
What is the business model for FOXO Labs after the spin-off?
Who are the key executives involved in FOXO's spin-off announcement?
